CN Mobile Logo


Leukemia & Lymphoma

Leukemia & Lymphoma

Patients with chronic lymphocytic leukemia (CLL) taking ibrutinib showed an antibody response to the influenza vaccine, according to a data from a small study.

Patients with adult T-cell leukemia/lymphoma treated with mogamulizumab prior to undergoing allo-HSCT were at significantly greater risk for graft-vs-host disease–related mortality.

In this review, we discuss the potential applications of monitoring ctDNA in patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

It is clear that as our understanding of both aggressive and indolent lymphomas improves, the goals of treatment change and the bar for success is set higher.

An 84-year-old woman with a history of Graves disease, hyperlipidemia, and hypertension presented to her physician with progressive fatigue and palpable bilateral axillary lymphadenopathy.

A propensity score–matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.

Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors.


Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.